Importantly, these SEs depend on the chromatin remodeler BRG1 (SMARCA4) to sustain the MYC oncogenic transcriptional program, thereby driving AML progression (Shi et al., 2013). The gene discussed is SMARCA4; the disease is acute myeloid leukemia.